title: Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
abstract: Chemotherapy-induced nausea and vomiting (CINV) remains both a feared side effect of cancer treatment and a focus of many supportive care initiatives/guidelines. The class of medications known as serotonin receptor antagonists (5-HT3RAs) are integral in the prevention of CINV from both moderately and highly emetogenic chemotherapy. Palonosetron (ALOXI(®)), a second-generation 5-HT3RA, has a higher affinity for the 5-HT3 receptor, has a longer half-life and has unique interactions with the 5-HT3 receptor compared with the current first-generation 5-HT3RA such as ondansetron, granisetron, dolasetron and tropisetron. This may allow palonosetron an advantage in control of CINV. This review article examines the available evidence, the pharmacokinetics and the safety and tolerability of palonosetron in the prevention of CINV.
authors.affiliation: Arthur G. James Cancer Hospital & Richard J. Solove Research Institute, The Ohio State University, The Martha Morehouse Medical Plaza, 2050 Kenny Road, Suite 377 Tower Building, Columbus, OH 43221, USA. Sherry.MoriVogt@osumc.edu
authors.forename: Sherry
authors.initials: S
authors.lastname: Mori-Vogt
authors.forename: Marlo
authors.initials: M
authors.lastname: Blazer
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D060828:Induction Chemotherapy / Q000009:adverse effects*; D007546:Isoquinolines / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D009369:Neoplasms / Q000188:drug therapy*; D000077924:Palonosetron; D011812:Quinuclidines / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000970:Antineoplastic Agents; D007546:Isoquinolines; D011812:Quinuclidines; D000077924:Palonosetron